82 FR 25805 - National Institute on Aging; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 106 (June 5, 2017)

Page Range		25805-25806
FR Document		2017-11497

Federal Register, Volume 82 Issue 106 (Monday, June 5, 2017)

[Federal Register Volume 82, Number 106 (Monday, June 5, 2017)]
[Notices]
[Pages 25805-25806]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-11497]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; Microbiome and Antibiotic Resistance in Elders Study 
(MARvELS).
    Date: June 19, 2017.
    Time: 1:30 p.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 2W200, 
7201 Wisconsin Avenue, Bethesda, MD 20892.
    Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review 
Officer, National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; A Global Perspective on Cognition and Dementia.
    Date: June 22, 2017.
    Time: 1:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, 2W200, 
7201 Wisconsin Avenue, Bethesda, MD 20892.
    Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review 
Officer, National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703, 
[email protected].

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; Pragmatic Trials for Dementia Care.
    Date: June 23, 2017.
    Time: 2:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, Suite 
2W200, 7200 Wisconsin Avenue, Bethesda, MD (Telephone Conference 
Call).
    Contact Person: Carmen Moten, MPH, Ph.D., Scientific Review 
Officer, National Institute on Aging, Gateway Building, 7201 
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7703.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)


[[Page 25806]]


    Dated: May 30, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-11497 Filed 6-2-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices 25805

claiming priority to the aforementioned New York, in the United States, and The meetings will be closed to the
applications. within 3 years the virus had spread to public in accordance with the
E–006–2007/0, Pletnev et al., most of the contiguous U.S. and the provisions set forth in sections
‘‘Synergistic Internal Ribosome Entry neighboring countries of Canada and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Site/MicroRNA Based Approach for Mexico. In addition, although few as amended. The grant applications and
Attenuation of Flaviviruses and Live human cases have been reported, WNV the discussions could disclose
Vaccine Development,’’ U.S. Provisional has also been found in Central and confidential trade secrets or commercial
Patent Application Number 62/443,214, South America through surveillance property such as patentable material,
filed January 6, 2017, and U.S. and studies in field specimens, suggesting a and personal information concerning
foreign patent applications claiming potential risk for an outbreak in individuals associated with the grant
priority to the aforementioned humans. In the approximately eighty applications, the disclosure of which
applications. (80) years since its discovery, the virus would constitute a clearly unwarranted
The patent rights in these inventions has propagated to a vast region of the invasion of personal privacy.
have been assigned to the government of globe and is now considered the most
the United States of America. Name of Committee: National Institute on
important causative agent of viral Aging Special Emphasis Panel; Microbiome
The prospective exclusive license encephalitis worldwide.
territory may be worldwide and the and Antibiotic Resistance in Elders Study
No vaccine exists today to prevent (MARvELS).
field of use may be limited to live WNV. The methods and compositions of
attenuated West Nile Virus vaccines for Date: June 19, 2017.
this invention provide a means for Time: 1:30 p.m. to 5:30 p.m.
use in humans or animals. prevention of WNV infection by
West Nile virus (WNV) is a positive- Agenda: To review and evaluate grant
immunization with live attenuated, applications.
strand RNA virus of the family immunogenic viral vaccines against
Flaviviridae, part of the Japanese Place: National Institute on Aging,
WNV. Gateway Building, 2W200, 7201 Wisconsin
encephalitis virus serocomplex that This notice is made in accordance Avenue, Bethesda, MD 20892.
includes important human pathogens with 35 U.S.C. 209 and 37 CFR part 404. Contact Person: Carmen Moten, Ph.D.,
such as Murray Valley encephalitis, The prospective exclusive license will MPH, Scientific Review Officer, National
Japanese encephalitis, and St. Louis be royalty bearing, and the prospective Institute on Aging, Gateway Building, 7201
encephalitis viruses. WNV has been exclusive license may be granted unless Wisconsin Avenue, Suite 2C212, Bethesda,
present in Africa and Asia for decades within fifteen (15) days from the date of MD 20892, 301–402–7703, cmoten@
and has usually been associated with this published notice, the National mail.nih.gov.
mild illness that includes symptoms of Institute of Allergy and Infectious
low-grade fever, headache, rash, This notice is being published less than 15
Diseases receives written evidence and days prior to the meeting due to the timing
myalgia, and arthralgia. Recently, WNV argument that establishes that the grant
has spread rapidly across the Western limitations imposed by the review and
of the license would not be consistent funding cycle.
hemisphere and is now the major
with the requirements of 35 U.S.C. 209 Name of Committee: National Institute on
vector-borne cause of viral encephalitis
and 37 CFR part 404. Aging Special Emphasis Panel; A Global
in the United States. By 2010, 3 million Complete applications for a license in
adults were estimated to have been Perspective on Cognition and Dementia.
the prospective field of use that are filed Date: June 22, 2017.
infected with WNV in the United States, in response to this notice will be treated
with nearly 13,000 cases of Time: 1:30 p.m. to 4:30 p.m.
as objections to the grant of the Agenda: To review and evaluate grant
neuroinvasive disease, almost half of contemplated Exclusive
which occurred in adults greater than 60 applications.
Commercialization Patent License Place: National Institute on Aging,
years of age. In this age group, WNV
Agreement. Comments and objections Gateway Building, 2W200, 7201 Wisconsin
infection can cause hepatitis,
submitted to this notice will not be Avenue, Bethesda, MD 20892.
meningitis, and encephalitis, leading to
made available for public inspection Contact Person: Carmen Moten, Ph.D.,
paralysis, coma, and death. WNV is
and, to the extent permitted by law, will MPH, Scientific Review Officer, National
considered an emerging infection in the Institute on Aging, Gateway Building, 7201
not be released under the Freedom of
United States and presents a significant Wisconsin Avenue, Suite 2C212, Bethesda,
Information Act, 5 U.S.C. 552.
public health threat. This MD 20892, 301–402–7703, cmoten@
epidemiological trend of WNV suggests Dated: May 24, 2017.
mail.nih.gov.
that the United States can expect Suzanne Frisbie,
Name of Committee: National Institute on
periodic WNV outbreaks, underscoring Deputy Director, Technology Transfer and
Aging Special Emphasis Panel; Pragmatic
the need for a safe and effective vaccine Intellectual Property Office, National Institute
Trials for Dementia Care.
to protect at-risk populations, especially of Allergy and Infectious Diseases.
Date: June 23, 2017.
older adults. [FR Doc. 2017–11491 Filed 6–2–17; 8:45 am]
Time: 2:30 p.m. to 4:30 p.m.
WNV is also a significant worldwide BILLING CODE 4140–01–P Agenda: To review and evaluate grant
public health threat. Starting in the mid- applications.
1990s, the frequency, severity, and Place: National Institute on Aging,
geographic range of WNV outbreaks DEPARTMENT OF HEALTH AND Gateway Building, Suite 2W200, 7200
increased, and outbreaks of WNV HUMAN SERVICES Wisconsin Avenue, Bethesda, MD
asabaliauskas on DSKBBXCHB2PROD with NOTICES

meningitis and encephalitis affecting (Telephone Conference Call).
primarily adults struck Bucharest, National Institutes of Health Contact Person: Carmen Moten, MPH,
Romania, in 1996, Volgograd, Russia, in Ph.D., Scientific Review Officer, National
National Institute on Aging; Notice of
1999, and Israel, in 2000. WNV crossed Institute on Aging, Gateway Building, 7201
Closed Meetings
the Atlantic and reached the Western Wisconsin Avenue, Suite 2C212, Bethesda,
hemisphere in the summer of 1999 Pursuant to section 10(d) of the MD 20892, 301–402–7703.
when a cluster of patients with Federal Advisory Committee Act, as (Catalogue of Federal Domestic Assistance
encephalitis was reported in the amended (5 U.S.C. App.), notice is Program Nos. 93.866, Aging Research,
metropolitan area of New York City, hereby given of the following meetings. National Institutes of Health, HHS)

VerDate Sep<11>2014 17:31 Jun 02, 2017 Jkt 241001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1

25806 Federal Register / Vol. 82, No. 106 / Monday, June 5, 2017 / Notices

Dated: May 30, 2017. conjunction with anti-malarials to treat provisions set forth in sections
David Clary, children with HCM. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Program Analyst, Office of Federal Advisory The inventors, listed below, have as amended. The grant applications and
Committee Policy. discovered that glutamine antagonists the discussions could disclose
[FR Doc. 2017–11497 Filed 6–2–17; 8:45 am] can be used to treat mice with confidential trade secrets or commercial
BILLING CODE 4140–01–P
experimental cerebral malaria (ECM) in property such as patentable material,
conjunction with anti-malarials. It was and personal information concerning
found that glutamine antagonist, 6- individuals associated with the grant
DEPARTMENT OF HEALTH AND diazo-5-L-norleucine (DON) applications, the disclosure of which
HUMAN SERVICES successfully restored blood-brain barrier would constitute a clearly unwarranted
integrity and decreased brain swelling invasion of personal privacy.
National Institutes of Health in ECM mice. This finding suggests that
Name of Committee: National Institute of
glutamine antagonists may be effective Diabetes and Digestive and Kidney Diseases
Government-Owned Inventions; in treating neurological damage in HCM Special Emphasis Panel; NIDDK Research
Availability for Licensing patients. Project Grants.
AGENCY: National Institutes of Health, This technology is available for Date: June 20, 2017.
HHS. licensing for commercial development Time: 3:00 p.m. to 4:00 p.m.
in accordance with 35 U.S.C. 209 and 37 Agenda: To review and evaluate grant
ACTION: Notice. CFR part 404, as well as for further applications.
development and evaluation under a Place: National Institutes of Health, Two
SUMMARY: The inventions listed below
research collaboration. Democracy Plaza, 6707 Democracy
are owned by an agency of the U.S. Boulevard, Bethesda, MD 20892 (Telephone
Government and are available for Potential Commercial Applications:
licensing to achieve expeditious • Therapeutic for cerebral malaria Conference Call).
Competitive Advantages: Contact Person: Elena Sanovich, Ph.D.,
commercialization of results of • Effective adjunctive therapeutics for Scientific Review Officer, Review Branch,
federally-funded research and cerebral malaria are not available. DEA, NIDDK, National Institutes of Health,
development. Foreign patent Development Stage: Pre-Clinical. Room 7351, 6707 Democracy Boulevard,
applications are filed on selected Bethesda, MD 20892–2542, 301–594–8886,
Inventors: Susan K. Pierce, NIAID,
inventions to extend market coverage sanoviche@mail.nih.gov.
NIH, Johnathan Powell, Johns Hopkins
for companies and may also be available Name of Committee: National Institute of
University.
for licensing. Diabetes and Digestive and Kidney Diseases
Publications: Gordon, Emile B., et al.
Special Emphasis Panel; Time-Sensitive
FOR FURTHER INFORMATION CONTACT: (2015) Targeting glutamine metabolism Obesity.
Chris Kornak, J.D., 240–627–3705, rescues mice from late-stage cerebral Date: June 21, 2017.
chris.kornak@nih.gov. Licensing malaria. PNAS 112(42): 13075–13080. Time: 10:30 a.m. to 12:00 p.m.
information and copies of the U.S. Intellectual Property: HHS Reference Agenda: To review and evaluate grant
patent applications listed below may be No. E–202–2015/0—US Provisional applications.
obtained by communicating with the Patent Application No. 62/175,000 filed Place: National Institutes of Health, Two
indicated licensing contact at the June 12, 2015; PCT Patent Application Democracy Plaza, 6707 Democracy
Technology Transfer and Intellectual No. PCT/US2016/036996 filed June 10, Boulevard, Bethesda, MD 20892 (Telephone
Property Office, National Institute of 2016. Conference Call).
Allergy and Infectious Diseases, 5601 Licensing Contact: Chris Kornak, J.D., Contact Person: Michele L. Barnard, Ph.D.,
240–627–3705, chris.kornak@nih.gov. Scientific Review Officer, Review Branch,
Fishers Lane, Rockville, MD, 20852; tel. DEA, NIDDK, National Institutes of Health,
301–496–2644. A signed Confidential Collaborative Research Opportunity:
Room 7353, 6707 Democracy Boulevard,
Disclosure Agreement will be required For collaboration opportunities, please
Bethesda, MD 20892–2542, (301) 594–8898,
to receive copies of unpublished patent contact Chris Kornak, J.D. 240–627– barnardm@extra.niddk.nih.gov.
applications. 3705, chris.kornak@nih.gov.
Name of Committee: National Institute of
SUPPLEMENTARY INFORMATION: Dated: May 24, 2017. Diabetes and Digestive and Kidney Diseases
Technology description follows. Suzanne Frisbie, Special Emphasis Panel; Preventing Type 2
Deputy Director, Technology Transfer and Diabetes.
Methods for Treating Cerebral Edema Date: June 28, 2017.
Intellectual Property Office, National Institute
and Restoring Blood-Brain Barrier of Allergy and Infectious Diseases. Time: 10:00 a.m. to 11:00 a.m.
Integrity Agenda: To review and evaluate grant
[FR Doc. 2017–11492 Filed 6–2–17; 8:45 am]
applications.
Description of Technology: There are BILLING CODE 4140–01–P Place: National Institutes of Health, Two
nearly 600 million clinical cases of Democracy Plaza, 6707 Democracy
Plasmodium falciparum malaria Boulevard, Bethesda, MD 20892 (Telephone
annually. For most individuals living in DEPARTMENT OF HEALTH AND Conference Call).
endemic areas, malaria is HUMAN SERVICES Contact Person: Michele L. Barnard, Ph.D.,
uncomplicated and resolves with time. Scientific Review Officer, Review Branch,
However, malaria can become severe National Institutes of Health DEA, NIDDK, National Institutes of Health,
and life threatening in young children, Room 7353, 6707 Democracy Boulevard,
National Institute of Diabetes and Bethesda, MD 20892–2542, (301) 594–8898,
asabaliauskas on DSKBBXCHB2PROD with NOTICES

which resulted in 429,000 deaths in
2015. One of the most deadly Digestive and Kidney Diseases; Notice barnardm@extra.niddk.nih.gov.
complications of P. falciparum infection of Closed Meetings Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
is cerebral malaria (HCM) characterized Pursuant to section 10(d) of the Special Emphasis Panel; NIDDK PTH
by the onset of severe neurological signs Federal Advisory Committee Act, as Receptor (P01).
such as altered consciousness, seizures, amended (5 U.S.C. App.), notice is Date: July 25, 2017.
and coma. Thus, there is an urgent need hereby given of the following meetings. Time: 12:00 p.m. to 2:00 p.m.
for the development of effective The meetings will be closed to the Agenda: To review and evaluate grant
adjunctive therapies that can be used in public in accordance with the applications.

VerDate Sep<11>2014 17:31 Jun 02, 2017 Jkt 241001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\05JNN1.SGM 05JNN1

Document Created: 2018-11-14 10:00:32
Document Modified: 2018-11-14 10:00:32

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		June 19, 2017.
FR Citation		82 FR 25805

82 FR 25805 - National Institute on Aging; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 106 (June 5, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health